Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report
نویسندگان
چکیده
A 67-year-old Asian woman was referred to Kurume University Hospital due to abnormal liver function tests. She was diagnosed with nonalcoholic fatty liver disease (NAFLD). NAFLD was treated by diet therapy with medication of metformin and pioglitazone; however, NAFLD did not improve. Subsequently, the patient was administered sitagliptin. Although her energy intake and physical activity did not change, her hemoglobin A1c level was decreased from 7.8 to 6.4% 3 months after treatment. Moreover, her serum insulin level and homeostasis model assessment-insulin resistance value were also improved, as was the severity of hepatic steatosis. These findings indicate that sitagliptin may improve insulin resistance and steatosis in patients with refractory NAFLD.
منابع مشابه
Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function
Novel therapies are needed for treating the increasing prevalence of hepatic steatosis in Western populations. In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently been reported to attenuate the development of hepatic steatosis, but the potential mechanisms remain poorly defined. In the current study, 4-week-old C57Bl/6 mice were fed a high-fat/high-fructose Western diet (WD)...
متن کاملNonalcoholic Fatty Liver Disease Treatment
Nonalcoholic fatty liver disease (NAFLD) is increasing in pediatric age group parallel to the growing prevalence of obesity and overweight all around the world. So changing in life style and interventions on obesogenic environment is cornerstone of NAFLD therapy in obese children. Some experts recommend that children and adolescents be encouraged to follow a low-fat, low-glycemic-index diet t...
متن کاملBenefit of Pitavastatin plus Sitagliptin Combination Treatment on Hyperinsulinemia and Fatty Liver Damage in Obese Mice
inhibitors) are used for the treatment of hyperlipidemia accompanied by obesity, and have been shown to reduce the risk of major cardiovascular events in a prospective metaanalysis [3]. Pitavastatin is a statin that has been reported to ameliorate severe steatohepatitis by enhancing hepatic free acid β-oxidation activity in aromatase-deficient (Ar-/-) mice [4]. It has also been shown to inhibit...
متن کاملMultidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders....
متن کاملThe Effect of Aerobic Continuous Training on Myonectin, Insulin Resistance and Liver Enzymes in Rats with Nonalcoholic Fatty Liver Disease
Background. Non-alcoholic fatty liver disease, is the most common reason of liver disorders that can be controlled by dieting and regular physical activity. Objectives. The aim of this study was to investigate the effect of aerobic continuous training on serum levels of myonectin, insulin resistance and liver enzymes in rats with non-alcoholic fatty liver disease. Methods. Thirty-four male W...
متن کامل